Safety and efficacy of non–vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation

[1] Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129:837–47. ChughSS HavmoellerR NarayananK SinghD RienstraM BenjaminEJ Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study Circulation 2014 129 837 47 10.1161/CIRCULATIONAHA.113.005119415130224345399 Search in Google Scholar

[2] Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6:213–20. Zoni-BerissoM LercariF CarazzaT DomenicucciS Epidemiology of atrial fibrillation: European perspective Clin Epidemiol 2014 6 213 20 10.2147/CLEP.S47385406495224966695 Search in Google Scholar

[3] Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider K. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J. 2013; 166:442–8. KirchhofP BreithardtG CammAJ CrijnsHJ KuckKH VardasP WegscheiderK Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial Am Heart J 2013 166 442 8 10.1016/j.ahj.2013.05.01524016492 Search in Google Scholar

[4] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–51. ConnollySJ EzekowitzMD YusufS EikelboomJ OldgrenJ ParekhA Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 2009 361 1139 51 10.1056/NEJMoa090556119717844 Search in Google Scholar

[5] Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–91. PatelMR MahaffeyKW GargJ PanG SingerDE HackeW Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 2011 365 883 91 10.1056/NEJMoa100963821830957 Search in Google Scholar

[6] Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–92. GrangerCB AlexanderJH McMurrayJJ LopesRD HylekEM HannaM Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 2011 365 981 92 10.1056/NEJMoa110703921870978 Search in Google Scholar

[7] Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093–104. GiuglianoRP RuffCT BraunwaldE MurphySA WiviottSD HalperinJL Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 2013 369 2093 104 10.1056/NEJMoa131090724251359 Search in Google Scholar

[8] Kim HM, Choi E-K, Park CS, Cha M-J, Lee S-Y, Kwon J-M, Oh S. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PLoS One. 2019; 14:e0211766. doi: 10.1371/journal.pone.0211766 KimHM ChoiE-K ParkCS ChaM-J LeeS-Y KwonJ-M OhS Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation PLoS One 2019 14 e0211766 10.1371/journal.pone.0211766640524430845196 Open DOISearch in Google Scholar

[9] Jung H, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. Chest. 2019; 155:354–63. JungH YangP-S JangE YuHT KimT-H UhmJ-S Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study Chest 2019 155 354 63 10.1016/j.chest.2018.11.00930472021 Search in Google Scholar

[10] Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69:236–9. RosendaalFR CannegieterSC van der MeerFJ BriëtE A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 1993 69 236 9 10.1055/s-0038-1651587 Search in Google Scholar

[11] Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3:692–4. SchulmanS KearonC Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 2005 3 692 4 10.1111/j.1538-7836.2005.01204.x15842354 Search in Google Scholar

[12] Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015; 12:e1001885. doi: 10.1371/journal.pmed.1001885 BenchimolEI SmeethL GuttmannA HarronK MoherD PetersenI RECORD Working Committee The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement PLoS Med 2015 12 e1001885 10.1371/journal.pmed.1001885459521826440803 Open DOISearch in Google Scholar

[13] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4:e296. doi: 10.1371/journal.pmed.0040296 von ElmE AltmanDG EggerM PocockSJ GøtzschePC VandenbrouckeJP STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies PLoS Med 2007 4 e296 10.1371/journal.pmed.0040296202049517941714 Open DOISearch in Google Scholar

[14] Chan Y-H, See L-C, Tu H-T, Yeh Y-H, Chang S-H, Wu L-S, et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018; 7:e008150. doi: 10.1161/JAHA.117.008150 ChanY-H SeeL-C TuH-T YehY-H ChangS-H WuL-S Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation J Am Heart Assoc 2018 7 e008150 10.1161/JAHA.117.008150601544229622587 Open DOISearch in Google Scholar

[15] Balcı KG, Balcı MM, Canpolat U, Şen F, Akboğa MK, Süleymanoğlu M, et al. Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. Anatol J Cardiol. 2016; 16:474–81. BalcıKG BalcıMM CanpolatU ŞenF AkboğaMK SüleymanoğluM Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation Anatol J Cardiol 2016 16 474 81 Search in Google Scholar

[16] Rosner B. Fundamentals of biostatistics. 5th ed. Duxbery, MA: Thomson Learning; 2000. RosnerB Fundamentals of biostatistics 5th ed. Duxbery, MA Thomson Learning 2000 Search in Google Scholar

[17] Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. Singapore: John Wiley & Sons; 2003. FleissJL LevinB PaikMC Statistical methods for rates and proportions 3rd ed. Singapore John Wiley & Sons 2003 10.1002/0471445428 Search in Google Scholar

[18] Ngamjarus C, Chongsuvivatwong V, McNeil E. n4Studies: sample size calculation for an epidemiological study on a smart device. Siriraj Med J. 2016; 68:160–70. NgamjarusC ChongsuvivatwongV McNeilE n4Studies: sample size calculation for an epidemiological study on a smart device Siriraj Med J 2016 68 160 70 Search in Google Scholar

[19] Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. PLoS One. 2016; 11:e0164076. doi: 10.1371/journal.pone.0164076 HaasS Ten CateH AccettaG AngchaisuksiriP BassandJP CammAJ Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry PLoS One 2016 11 e0164076 10.1371/journal.pone.0164076508502027792741 Open DOISearch in Google Scholar